Patent Application
20250170083
A sequence listing in electronic (XML file) format is filed with this application and incorporated herein by reference. The name of the XML file is “Sequence_Listing-1899.xml”; the file was created on Jan. 29, 2025; the size of the file is 3,840 bytes.
The present application relates to a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy.
Autosomal dominant polycystic kidney disease (ADPKD), an intractable genetic disease, progressively forms numerous cysts in the kidneys and progresses to end-stage renal failure in midlife or later. The causative genes for ADPKD are PKD1 in 85% of cases and PKD2 in 15% of cases. Studies have been conducted using experimental animals such as disease model mice and rats, in which these genes have been altered, but the complete pathogenesis has not been elucidated, nor therapies to effect radical cure been developed. Tolvaptan, the only clinically approved and used vasopressin V2 receptor antagonist, inhibits cyst enlargement and renal hypofunction, but has limited efficacy and is not a radical cure (Non Patent Literature 1). In addition, patients who take tolvaptan are subject to various behavioral restrictions, such as the need for frequent fluid intake to prevent the development of side effects such as dehydration and hypernatremia due to its strong diuretic effect, so there is a need to develop a radical therapeutic agent that improves patients' quality of life.
In recent years, research has been actively conducted to analyze the detailed pathology and search for therapeutic agents by generating iPS cells from the somatic cells of patients with intractable diseases or disease-specific iPS cells by introducing mutations into the causative genes of iPS cells derived from healthy individuals, and inducing the differentiation of these cells into the affected cell types in vitro, so as to prepare disease models that reproduce the pathology.
Non Patent Literature 1
Torres V E et al., N Engl J Med. 2012 Dec. 20; 367 (25): 2407-2418.
An object of the present application is to provide a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy.
The present application provides a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition comprises a retinoic acid receptor (RAR) agonist.
The present application provides a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition comprising a retinoic acid receptor (RAR) agonist.
The present inventors have generated for the first time an in vitro renal collecting duct cyst model from iPS cells, and thus have discovered a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy by using the model.
In this disclosure, when a numerical value is accompanied by the term “about”, it is intended to include the range of ±10% of that value. For example, “about 20” shall include “18 to 22”. The numerical range includes all numerical values between the two endpoints and the numerical values at both endpoints. The term “about” for range applies to both endpoints of that range. For example, “about 20 to 30” shall include “18 to 33”.
The present application provides a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition containing a retinoic acid receptor (RAR) agonist.
Ciliopathies are diseases caused by genetic mutations in primary cilia and related structures. Renal cystic ciliopathy refers to a ciliopathy complicated by renal cysts. Examples of the renal cystic ciliopathy include polycystic kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD, also known as “autosomal manifest polycystic kidney disease”) and autosomal recessive polycystic kidney disease (ARPKD, also known as “autosomal latent polycystic kidney disease”), nephronophthisis, Joubert syndrome, Barday-Biedl syndrome, Meckel-Gruber syndrome, oral-facial-digital syndrome type I, June syndrome, Senor-Lorken syndrome, and Alstrom syndrome. In one embodiment, the renal cystic ciliopathy is, for example, polycystic kidney disease and is preferably autosomal dominant polycystic kidney disease (ADPKD).
The Retinoic Acid Receptor (RAR) agonist is not particularly limited, as long as it is a substance that binds to and activates RARs. Examples of the RAR agonist include 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl] benzoic acid (TTNPB, CAS No: 71441-28-6), all-trans retinoic acid (ATRA, CAS No: 302-79-4), 9-cis-retinoic acid (also known as: alitretinoin, CAS No: 5300-03-8), 13-cis-retinoic acid (also known as: isotretinoin, CAS No: 4759-48-2), AM80 (also known as: tamibarotene, CAS No: 94497-51-5), AM580 (CAS No: 102121-60-8), AC261066 (CAS No: 870773-76-5), AC55649 (CAS No: 59662-49-6), AGN-190168 (also known as: tazarotene, CAS No: 118292-40-3), tazarotenic acid (CAS No: 118292-41-4), AGN-195183 (CAS No: 367273-07-2), BMS641 (CAS No: 369364-50-1), BMS753 (CAS No: 215307-86-1), BMS961 (CAS No: 185629-22-5), CD271 (also known as: adapalene, CAS No: 106685-40-9), CD437 (CAS No: 125316-60-1), CD1530 (CAS No: 107430-66-0), CD2314 (CAS No: 170355-37-0), CD5789 (also known as: trifarotene, CAS No: 895542-09-3), Ch55 (CAS No: 110368-33-7), etretinate (CAS No: 54350-48-0), acitretin (CAS No: 55079-83-9), and fenretinide (CAS No: 65646-68-6), as well as a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable hydrolyzable ester thereof. In one embodiment, the RAR agonist is at least one selected from the group consisting of TTNPB, ATRA, AM80, AM580, AGN-195183, CD271, CD1530, CD5789, Ch55, etretinate, and fenretinide, as well as a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable hydrolyzable ester thereof. In a further embodiment, the RAR agonist is at least one selected from the group consisting of AM80, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable hydrolyzable ester thereof. In another embodiment, the RAR agonist is at least one selected from the group consisting of TTNPB, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable hydrolyzable ester thereof. In another embodiment, the RAR agonist is at least one selected from the group consisting of ATRA, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable hydrolyzable ester thereof.
The term “pharmaceutically acceptable salt” refers to a salt that is not significantly toxic and can be used as a medicine. An example of the pharmaceutically acceptable salt is a base addition salt or an acid addition salt. Examples of the base addition salt include: alkali metal salts such as sodium salts, potassium salts, and lithium salts; alkaline earth metal salts such as calcium salts and magnesium salts; metal salts such as aluminum salts and iron salts; inorganic salts such as ammonium salts; organic amine salts such as t-octylamine salts, dibenzylamine salts, morpholine salts, glucosamine salts, ethylenediamine salts, N-methylglucamine salts, guanidine salts, diethylamine salts, triethylamine salts, dicyclohexylamine salts, N,N′-dibenzylethylenediamine salts, chloroprocaine salts, procaine salts, diethanolamine salts, N-benzylphenethylamine salts, piperazine salts, tetramethylammonium salts, and tris(hydroxymethyl)aminomethane salts; and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamic acid salts, and aspartic acid salts. Examples of the acid addition salt include: mineral acid salts such as hydrochlorides, sulfates, and nitrates; and organic acid salts such as methanesulfonates, paratoluenesulfonates, citrates, and oxalates.
The term “pharmaceutically acceptable hydrolyzable ester” refers to an ester that is hydrolyzed in vivo and includes those that are decomposed readily in the human body to release the parent compound or a salt thereof. Pharmaceutically acceptable hydrolyzable esters may be cleaved by esterases in vivo to give active compounds. Examples of pharmaceutically acceptable hydrolyzable esters include lower alkyl esters, lower alkenyl esters, lower alkylamino lower alkyl esters, acylamino lower alkyl esters, acyloxy lower alkyl esters, aryl esters, and aryl lower alkyl esters. The term “lower” means, for example, 1 to 6 or 1 to 4 carbon atoms.
Pharmaceutically acceptable hydrolyzable ester groups can also be derived, for example, from pharmaceutically acceptable aliphatic carboxylic acids (including alkanoic acids, alkenoic acids, cycloalkanoic acids, and alkanedioic acids). The alkyl or alkenyl group of the pharmaceutically acceptable aliphatic carboxylic acid may have, for example, 6 or less carbon atoms. Specific examples of hydrolyzable esters include formates, acetates, phosphates, propionates, butyrates, acrylates, and succinates.
The present application also provides a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition containing a vector expressing a CDKN2B gene.
The vector expressing the CDKN2B gene can be a plasmid vector or a viral vector. When the vector expressing the CDKN2B gene is a plasmid vector, the plasmid vector to be used is not particularly limited, and any plasmid vector such as a cloning plasmid vector or an expression plasmid vector can be used. When the vector expressing the CDKN2B gene is a viral vector, examples of the viral vector to be used include, but are not limited to, an adenovirus vector, an adeno-associated virus (AAV) vector, a lentivirus vector, a retrovirus vector, and a Sendai virus vector.
The vector expressing the CDKN2B gene can have a regulatory sequence that regulates the expression of the CDKN2B gene. Examples of the regulatory sequence include promoters, terminators, enhancers, polyadenylation signal sequences, and replication origin sequences. The regulatory sequence needs only be arranged to be able to functionally regulate the expression of the vector expressing the CDKN2B gene and can be arranged based on known methods.
The pharmaceutical composition of the present application can contain a pharmaceutically acceptable carrier or additive. Examples of such carriers or additives include isotonic agents, thickeners, sugars, sugar alcohols, preservatives, bactericides, antibacterial agents, pH adjusters, stabilizers, chelating agents, oil base agents, gel base agents, wetting agents, surfactants, suspending agents, binding agents, excipients, lubricants, disintegrants, foaming agents, fluidizing agents, dispersing agents, emulsifying agents, buffers, dissolution aids, and antioxidants. Pharmaceutically acceptable carriers or additives may be used singly or in a mixture of two or more.
The route of administration of the pharmaceutical composition of the present application is not particularly limited, including oral or parenteral administration. Various known forms of administration can be employed depending on a target disease. For example, parenteral administration may be systemic or local administration, and examples thereof include intratracheal administration, intravenous administration, intraarterial administration, intraportal administration, intradermal administration, subcutaneous administration, intramuscular administration, intraperitoneal administration, intranasal administration, and oral administration. In a preferred embodiment, when the subject is an animal, the pharmaceutical composition of the present application is administered intraperitoneally or orally. In a preferred embodiment, when the subject is a human, the pharmaceutical composition of the present application is administered orally.
Examples of the oral dosage forms include granules, fine granules, powder agents, coated tablets, tablets, suppositories, dispersions, capsules, microcapsules, chewables, liquids, suspensions, and emulsions. As the dosage form for administration by injection, general dosage forms of pharmaceutical preparations such as preparations for intravenous injection, preparations for intracoronary administration, preparations for drip administration, and preparations for prolonging the release of active substances can be employed. Injectable forms of administration may be provided in sealed ampules or vials, or as lyophilized products that only require the addition of a sterile liquid (e.g., water for injection) immediately before use. Injectable solutions or suspensions may be prepared from powder, granules or tablets. These dosage forms are produced by formulation according to the usual methods.
The dosage and frequency of administration of the pharmaceutical composition of the present application can be set adequately by a person skilled in the art according to animal species to be subjected to administration, the health condition, age, body weight, route of administration, and form of administration, etc., of a subject of administration, so that the effective amount of the active ingredient is administered to the subject. For example, the pharmaceutical composition of the present application can be administered once to several times a day, or once to several times a day or few days or a week or few weeks, such as once a week to four weeks, for example. However, examples thereof are not limited thereto. The effective dose in a given situation can be readily determined by routine experimentation and is within the skill and judgment of the ordinary clinician. For example, if the RAR agonist is TTNPB, about 0.001 to about 100 mg/kg body weight, about 0.01 to about 100 mg/kg body weight, about 0.05 to about 10 mg/kg body weight, or about 0.1 to about 5 mg/kg body weight of the RAR agonist can be administered orally. For example, if the RAR agonist is ATRA, about 0.1 to about 1,000 mg, about 1 to about 1,000 mg, about 10 to about 500 mg, about 50 to about 100 mg, or about 60 to 80 mg per day of the RAR agonist can be administered orally. For example, if the RAR agonist is 9-cis-retinoic acid, about 0.1 to about 1,000 mg, about 1 to about 1,000 mg, about 5 to about 100 mg, about 10 to about 50 mg, or about 30 mg per day of the RAR agonist can be administered orally. For example, if the RAR agonist is 13-cis-retinoic acid, about 0.001 to about 50 mg/kg body weight, about 0.01 to about 50 mg/kg body weight, about 0.05 to about 10 mg/kg body weight, about 0.1 to about 5 mg/kg body weight, or about 0.5 to about 1 mg/kg body weight per day of the RAR agonist can be administered orally. For example, if the RAR agonist is AM80, about 0.01 to about 100 mg/m2, about 0.1 to about 100 mg/m2, about 0.5 to about 50 mg/m2, about 1 to about 10 mg/m2, or about 6 mg/m2 per day of the RAR agonist can be administered orally.
The pharmaceutical composition of the present application may be used alone or in combination with one or more further active ingredients. Further active ingredients are, for example, active ingredients for treating and/or preventing renal cystic ciliopathy. The expression “used in combination” means not only the use of dosage form containing all ingredients and the combined use of dosage forms containing each ingredient separately, but also the simultaneous or sequential administration of each ingredient, or delayed administration of any ingredient, as long as they are used for treating and/or preventing renal cystic ciliopathy. Two or more further active ingredients may be used in combination.
As used herein, the term “treatment” means, in a subject with a disease, to reduce or eliminate the cause of the disease, to delay or halt the progression of the disease, to reduce, alleviate, ameliorate, or eliminate its symptoms, and/or to inhibit the worsening of its symptoms.
As used herein, the term “prevention” means to prevent the onset of a disease or reducing the likelihood of developing the disease in a subject. Here, disease onset includes recurrence. The subject is, for example, a subject who is likely to develop a disease but has not yet done so. Subjects who may develop renal cystic ciliopathy but have not yet done so include, for example, subjects with genetic predisposition to the renal cystic ciliopathy. Examples of genetic predisposition to the renal cystic ciliopathy include gene mutations in the causative genes for ADPKD (PKD1 and PKD2, etc.), the causative genes for ARPKD (e.g. PKHD1), the causative genes for nephronophthisis (NPHP1 to NPHP13, etc.), the causative genes for Joubert syndrome (JBTS1 to JBTS17, etc.), the causative genes for Bardet-Biedl syndrome (BBS1 to BBS15, etc.), the causative genes for Meckel-Gruber syndrome (MKS1 to MKS10, etc.), the causative genes for oral-facial-digital syndrome type I (e.g. OFD1), the causative genes for Jeune syndrome (e.g. IFT80), the causative genes for Senior-Loken syndrome (NPHP1, NPHP3 to NPHP6, etc.), or the causative genes for Alstrom syndrome (e.g. ALMS1).
Examples of subjects for treatment and/or prevention of the disease include mammals such as mice, rats, hamsters, guinea pigs, cattle, horses, pigs, sheep, monkeys, orangutans, chimpanzees, dogs, cats, and humans, preferably primates, and more preferably humans.
The present application also provides a method for treating renal cystic ciliopathy, which involves administering the pharmaceutical composition of the present application to a subject in need thereof. The present application also provides the use of an RAR agonist for the manufacture of the pharmaceutical composition for treating renal cystic ciliopathy. The present application further provides an RAR agonist for use in the treatment of renal cystic ciliopathy. Examples of renal cystic ciliopathy and the RAR agonist are as described above.
The present application also provides a method for preventing renal cystic ciliopathy, which involves administering the pharmaceutical composition of the present application to a subject in need thereof. The present application also provides the use of the RAR agonist for the manufacture of the pharmaceutical composition for preventing renal cystic ciliopathy. The present application further provides the RAR agonist for use in the prevention of renal cystic ciliopathy. Examples of the renal cystic ciliopathy and the RAR agonist are as described above.
The following examples are provided for further description, but the present invention is not limited to these examples in any way.
Experiments using human induced pluripotent stem cells were approved by the Ethics Committee of the Faculty of Medicine and Graduate School of Medicine, Kyoto University. The 1383D2 cell line was used as a human iPS cell line. PKD1 knockout iPS cells were prepared using the CRISPR-Cas9 regulated transcription and nuclear shuttling (CRONUS) system based on a previously reported DNA transposon (Ishida K. et al, Sci Rep. 8: 310 (2018); Shimizu T. et al., Biochem Biophys Res Commun. 529, 1186-1194 (2020)). Cells were continuously transfected with a CRONUS-Puro vector (pPV-TetO-SphcCas9-GR-iC-A-EF1α-rtTA-iP, Addgene ID 100596) and a piggyBac vector for cloning sgRNA (pPV-H1-ccdB-mEF1α-RiH, Addgene ID 100598) together with a piggyBac transposase expression plasmid (pHL-EF1α-hcPBase-A, Addgene ID 100599) through lipofection using FuGENE6 (Promega). The CRONUS-Puro vector and the piggyBac vector for cloning sgRNA were compatible with puromycin selection and hygromycin selection, respectively. The following sequence: 5′-GAGACCACTTGGATCCGGGATCAGGTCTTCATCTAGGTTTTAGAGCTAGAAATAGCA-3′ (SEQ ID NO: 1, the target site is underlined) was used to clone the gRNA sequence targeting the PKD1 exon 34 splicing acceptor site into the pPV-H1-ccdB-mEF1α-RiH vector. RFP+ colonies were manually harvested by drug selection of transfected cells and treated with doxycycline and dexamethasone to induce genome editing. Individual colonies were screened for in terms of genome editing efficiency by Sanger sequencing of bulk genomic DNA. Single cells were then isolated by flow cytometry, clonally grown in 24-well culture plates (Corning) coated with iMatrix-511 (Nippi), and then genotyped by Sanger sequencing. Genome editing resulted in the generation of frameshifts and immature termination codons. Two bases (AG) at different sites within exon 34 functioned as splicing acceptor sequences, resulting in the generation of two types of PKD1 mutant mRNA. The primer sequences used in this example are listed in Table 1.
PKD1 knockout iPS cells were induced to differentiate into ureteric bud organoids as previously described (Mae, S I. & Ryosaka, M. et al. Cell Reports 32, 107963, 2020).
Ureteric bud organoids derived from PKD1 knockout iPS cells were treated with Accutase (Innovative Cell Technologies) at 37° C. for 5 minutes and then dissociated into single cells by pipetting. Cells were suspended in DMEM/F12 medium (Gibco) containing B27 supplement (vitamin A-free) (Gibco), 3 μM CHIR99021 (StemRD), 0.1 μM TTNPB (Santa Cruz), 200 ng/ml FGF1 (R&D systems), 100 ng/ml GDNF (R&D systems), 10 μM Thiazovivin (Santa Cruz Biotechnology), and 1 μM A83-01 (Wako). Single cells were seeded at 1.0×105 cells/well into each well of a 48-well plate coated with 150 μL of hydrogel. The hydrogel was composed of DMEM/F12 medium containing 50% Matrigel (BD Biosciences) and was allowed to solidify for 1 hour at 37° C. before use. Single cells established ureteric bud tip cell colonies after 7 days. The medium was exchanged every 2 to 3 days.
The hydrogel was dissolved with Cell Recovery Solution (Corning) for 30 minutes at 4° C., and then ureteric bud tip cell colonies were isolated. After further washing with Cell Recovery Solution at 4° C. for 30 minutes, ureteric bud tip cell colonies were centrifuged at 500 g for 5 minutes at room temperature. Ureteric bud tip cell colonies were treated with Accutase at 37° C. for 5 minutes and then dissociated into single cells by pipetting. Cells were suspended in DMEM/F12 medium containing B27 supplement (vitamin A-free), 3 μM CHIR99021, 0.1 μM TTNPB, 200 ng/ml FGF1, 100 ng/ml GDNF, 10 μM Thiazovivin and 1 μM A83-01. Cells were seeded at 1.0×105 cells/well into each well of a 48-well plate coated with 150 μL hydrogel. The hydrogel was composed of DMEM/F12 medium containing 50% Matrigel and allowed to solidify for 1 hour at 37° C. before use. Ureteric bud tip cell colonies were prepared by culturing single cells at 37° C. with 5% CO2 for 7 days. The medium was exchanged every 2 to 3 days. The prepared ureteric bud tip cell colonies were passaged every 7 days in the same manner. The tip cell colonies cultured for 4 to 6 weeks or longer were used to reconstitute the following collecting duct organoids.
The hydrogel was dissolved using Cell Recovery Solution at 4° C. for 30 minutes, so as to isolate ureteric bud tip cell colonies. After further washing with Cell Recovery Solution at 4° C. for 30 minutes, the ureteric bud tip cell colonies were centrifuged at 500 g for 5 minutes at room temperature. Ureteric bud tip cell colonies were treated with Accutase at 37° C. for 5 minutes and then dissociated into single cells by pipetting. Cells were suspended in Essential 6 medium (Gibco) containing 3 μM CHIR99021, 0.1 μM TTNPB, 200 ng/ml FGF1, 100 ng/ml GDNF, 10 μM Thiazovivin and 1 μM A83-01. Cells were seeded at 5.0×103 cells/well into 96-well low-adhesion plates (Sumitomo Bakelite). Single cells were cultured for 2 days at 37° C. with 5% CO2, thereby preparing spheroids.
Spheroids were suspended in Essential 6 medium containing 10% Afamin/Wnt3a conditioned medium (MBL), 200 ng/ml R-spondin 1 (R&D systems), 0.1 μM LDN193189 (Axon medchem), 200 ng/ml FGF1, 200 ng/ml FGF8 (Peprotech), 100 ng/ml GDNF, 0.1 μM TTNPB, 50 ng/ml EGF (R&D systems), 1 μM A83-01 and 10% Matrigel, and then distributed in 35 mm low-adhesion dishes (Sumitomo Bakelite) at 2.5 to 3 mL/dish. The medium was exchanged every 3 to 4 days. Spheroids were cultured at 37° C. with 5% CO2 for 14 to 21 days, thereby preparing artificial collecting duct organoids.
RNA sequence library preparation, sequencing, mapping and gene expression analysis were performed at DNAFORM. The quality of total RNA was evaluated using a Bioanalyzer (Agilent Technologies) and the RNA Integrity Number was confirmed to be 7.0 or greater. After enrichment of poly (A)+RNA by the use of the NEBNext Poly (A) mRNA Magnetic Isolation Module (New England BioLabs), Double-stranded cDNA libraries (RNA-seq library) were prepared according to the manufacturer's instructions using a SMARTer Stranded Total RNA Seq Kit v2 Pico Input Mammalian (Clontech). RNA-seq libraries were sequenced using paired-end reads (50 nt read 1 and 25 nt read 2) on a NextSeq 500 system (Illumina). The obtained reads were mapped to the human GRCh38 genome using STAR (version 2.7.2b) or Hisat2 (version 2.1.0). Reads of annotated genes were counted using featureCounts (version 1.6.1). FPKM and TPM values were calculated from the mapped reads by normalization with total counts. Differentially Expressed Genes (DEGs) were detected using the DESeq2 package (version 1.26.0). The list of DEGs detected by DESeq2 was used for GSEA. Heat maps and volcano plots were created using the bioinfokit package (version 2.0.1).
For comprehensive profiling of transcripts encoding human proteins, microarray analysis was performed at Filgen using the Human 8×60K LncRNA expression array (ArrayStar). Labeling of samples and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology). Data were collected using Agilent's Feature Extraction software. Raw signal intensities were normalized using the quantile normalization method of GeneSpring GX v12.1. Statistically significantly differentially expressed mRNAs between two groups were extracted by volcano plotting, followed by heat mapping and GSEA analysis.
Pkd1flox/flox: Ksp-cre mice, which are ADPKD model mice, develop numerous cysts progressively after birth and die at approximately 14 days of age due to renal failure.
Mouse lineages were maintained with heterozygous Pkd1flox/+: Ksp-Cre mice, and Pkd1flox/flox: Ksp-cre mice were generated by mating mice of the same lineage.
On postnatal day 3, Pkd1flox/flox: Ksp-cre mice (Cystic) and Pkd1flox/+: Ksp-Cre mice (Non-cystic) were intraperitoneally administered with ATRA (Sigma, #R2625) dissolved in sunflower oil containing 2% DMSO (solvent) to achieve a dose of 10 mg/kg. A group of mice administered with only the solvent intraperitoneally was served as a negative control. Mice were euthanized on postnatal day 9, and renal tissues and blood samples were collected.
On postnatal day 3, Pkd1flox/flox: Ksp-cre mice (Cystic) and Pkd1flox/+: Ksp-Cre mice (Non-cystic) were intraperitoneally administered with AM80 (Tamibarotene; Tocris, #3507) dissolved in sunflower oil containing 2% DMSO (solvent) to achieve a dose of 5 or 10 mg/kg. A group of mice administered with only the solvent intraperitoneally was served as a negative control. Mice were euthanized on postnatal day 9 and renal tissue samples were collected.
BUN in mouse serum was measured using an UN-L kit (Serotec, #A667-00).
Kidneys were fixed in 4% paraformaldehyde solution, and 4 μm-thick paraffin sections were prepared. After deparaffinization, HE staining was performed and renal tissues were photographed under an optical microscope. Cystic index was calculated by total cystic area/total renal tissue area×100 using image analysis and measurement software (WinROOF, Mitani Corporation).
Using PKD1 knockout iPS cells of the 1383D2 cell line, artificial collecting duct organoids with cystic structures were induced by the above method. The following protocol was used to examine compounds that inhibit cyst enlargement.
Cyst enlargement-inhibiting compounds to be evaluated in step 14 were added. TTNPB (Santa cruz, #sc-203303), AM80 (Cyman, #CAY-71770) and ATRA (Sigma, #R2625) were added to achieve a dose of 0.1 μM. RAR agonists (CD271, fenretinide, AM580, etretinate, CD1530, Ch55, AGN-195183, and CD5789) were added to achieve a dose of 1 μM.
The effects of TTNPB, a potent Retinoic Acid Receptor (RAR) agonist, were examined as a cyst enlargement-inhibiting compound.
TTNPB is an analogue of all-trans retinoic acid (ATRA). ATRA treatment also reduced the cyst sizes (
Next, the effects of AM80 (Tamibarotene) were examined as a cyst enlargement-inhibiting compound.
Next, the effects of various RAR agonists (CD271 (adapalene), fenretinide, AM580, etretinate, CD1530, Ch55, AGN-195183, and CD5789 (trifarotene)) were examined. With the cyst enlargement rate in the case of 10 μM forskolin as 100% and that in the case of 0.1 μM rapamycin as 0%, the cyst enlargement rate in the case of each RAR agonist (1 μM) was calculated (
To clarify the mechanism of action of TTNPB, gene expression in cyst cells cultured with and without TTNPB was compared by microarray (
The heat map revealed that the expression levels of MMP1, SLC2A1, CFTR, and HMGCR were decreased by TTNPB (
Furthermore, the heatmap revealed that TTNPB promotes the expression of cellular senescence marker genes such as CDKN2B (p15) (
These results indicate that retinoic acid agonists such as TTNPB and ATRA inhibit the enlargement of collecting duct cysts. The results also suggest that retinoid signaling is one of the mechanisms that inhibit cyst enlargement.
Since ATRA has already been used as a therapeutic agent for Acute Promyelocytic Leukemia (APL) patients, the efficacy of ATRA in ADPKD model mice was examined from a drug repositioning perspective. To reflect the in vitro results of ATRA on collecting duct cyst enlargement in in vivo, Pkd1flox/flox:Ksp-Cre mice, in which the Pkd1 allele is conditionally inactivated under expression of kidney-specific Ksp-Cre recombinase in the distal nephron segments and collecting ducts, were used. The mice develop renal failure from birth due to progressive cyst formation and die about 2 weeks after birth. Because Ksp cadherin is specifically expressed in the collecting ducts and distal tubules, cysts originating from the collecting ducts and distal tubules are formed in these ADPKD model mice. ATRA was administered at 10 mg/kg intraperitoneally to mice on postnatal day 3 (P3), and mice were then sacrificed at P9 (
No significant body weight loss due to ATRA treatment was observed, suggesting no significant side effects from ATRA (
Next, renal tissue sections were evaluated by hematoxylin-eosin (HE) staining (
ADPKD model mice exhibited elevated BUN (blood urea nitrogen) levels, an indicator of renal failure, and renal failure occurred. The BUN levels in mice treated with ATRA were significantly lower than those in control mice treated with a solvent (
These results demonstrated that ATRA inhibits cyst enlargement in collecting ducts and distal tubules in the in vivo ADPKD model. ATRA was demonstrated to exhibit therapeutic effects on both in vitro and in vivo ADPKD models.
The inhibitory effect of CDKN2B overexpression on cyst enlargement was examined using the following protocol.
iPS cells in which CDKN2B expression can be conditionally induced using doxycycline were established, preparing renal collecting duct cysts.
The efficacy of AM80 in ADPKD model mice was examined. To reflect the in vitro results of AM80 on collecting duct cyst enlargement in in vivo, Pkd1flox/flox:Ksp-Cre mice, in which the Pkd1 allele is conditionally inactivated under the expression of kidney-specific Ksp-Cre recombinase in the distal nephron segments and collecting ducts, were used. These mice develop renal failure due to progressive cyst formation from birth and die about 2 weeks after birth. Since Ksp cadherin is specifically expressed in the collecting ducts and distal tubules, cysts originating from the collecting ducts and distal tubules are formed in these ADPKD model mice. AM80 was administered intraperitoneally at 5 or 10 mg/kg to mice on postnatal day 3 (P3), and the mice were sacrificed at P9 (
When 10 mg/kg AM80 was administered to ADPKD model mice, the ratio of kidney weights to body weight (2 KW/BW) was significantly decreased (
Next, renal tissue sections were evaluated by hematoxylin-eosin (HE) staining (
These results demonstrated that AM80 inhibits cyst enlargement in collecting ducts and distal tubules in the in vivo ADPKD model. It was demonstrated that AM80 exhibits therapeutic effects on both in vitro and in vivo ADPKD models.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2022-171387 | Oct 2022 | JP | national |
This application is a continuation of International Application No. PCT/JP2023/038716, filed on Oct. 26, 2023 which claims the benefit of Japan Patent Application No. 2022-171387 filed on Oct. 26, 2022, the entire contents of which are incorporated by reference herein.
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/JP2023/038716 | Oct 2023 | WO |
| Child | 19041480 | US |
